Abstract
Aim: Recent evidence indicates increased risks of COVID-19 morbidity and mortality among individuals with substance use disorder, with a possible female disadvantage for opioid use disorder (OUD) contrary to males in the general population. COVID-19 outcomes have yet to be assessed using sex-stratified data to identify differential impacts between males and females. Study aims were to: (1) Report sex-specific COVID-19 outcomes, opioid overdose, and mortality among individuals with OUD at a public safety net health system; (2) Assess sex-specific factors associated with 60-day all-cause, in-hospital mortality within a socioecological framework.
Methods: All patients receiving a SARS-CoV-2 test in year 2020 with OUD (ICD-10 and/or buprenorphine/ naltrexone prescription) were included. Bioinformatic search criteria abstracted outcomes from the medical record from January 1, 2020, through 60 days after the SARS-CoV-2 test. Analysis was performed in SAS. Chi-squared and Student t-tests assessed differences by sex. Multivariable regression was used for Aim 2, with results pending at this time.
Results: Data was abstracted for 2,600 patients with OUD (1,294 males; 1,306 females). A third were over 60 years, and the majority were Black (52%) with public insurance (Medicaid 28%, Medicare 31%). Most were overweight (male mean BMI 28) or obese (female mean BMI 31; p<0.001). Approximately half were smoking cigarettes (male 52%, female 40%; p<0.001). Across sex, 5% had a positive SARS-CoV-2 test (p=0.42) with similar incidences of hospitalization, ICU admission, and mechanical ventilator use. More males (10%) presented with an overdose than females (4%; p<0.001) and died as a result (males n=5; females n=0). However, 60-day all-cause, in-hospital mortality did not differ by sex (males 5%, females 4%; p=0.42).
Conclusions: Sex is an important biological variable that modifies health, including OUD and COVID-19. Within a majority Black population, COVID-19 outcomes were similar across sex, but males and females with OUD may differ in predisposing factors.
Methods: All patients receiving a SARS-CoV-2 test in year 2020 with OUD (ICD-10 and/or buprenorphine/ naltrexone prescription) were included. Bioinformatic search criteria abstracted outcomes from the medical record from January 1, 2020, through 60 days after the SARS-CoV-2 test. Analysis was performed in SAS. Chi-squared and Student t-tests assessed differences by sex. Multivariable regression was used for Aim 2, with results pending at this time.
Results: Data was abstracted for 2,600 patients with OUD (1,294 males; 1,306 females). A third were over 60 years, and the majority were Black (52%) with public insurance (Medicaid 28%, Medicare 31%). Most were overweight (male mean BMI 28) or obese (female mean BMI 31; p<0.001). Approximately half were smoking cigarettes (male 52%, female 40%; p<0.001). Across sex, 5% had a positive SARS-CoV-2 test (p=0.42) with similar incidences of hospitalization, ICU admission, and mechanical ventilator use. More males (10%) presented with an overdose than females (4%; p<0.001) and died as a result (males n=5; females n=0). However, 60-day all-cause, in-hospital mortality did not differ by sex (males 5%, females 4%; p=0.42).
Conclusions: Sex is an important biological variable that modifies health, including OUD and COVID-19. Within a majority Black population, COVID-19 outcomes were similar across sex, but males and females with OUD may differ in predisposing factors.
| Original language | English |
|---|---|
| Number of pages | 1 |
| Publication status | Published - 21 Jun 2021 |
| Event | The College on Problems of Drug Dependence: 2nd CPDD Virtual Scientific Meeting - Online, United States Duration: 21 Jun 2021 → 24 Jun 2021 https://cpdd.org/meetings/past-meeting-recaps/ |
Conference
| Conference | The College on Problems of Drug Dependence |
|---|---|
| Abbreviated title | 2021 CPDD |
| Country/Territory | United States |
| Period | 21/06/21 → 24/06/21 |
| Internet address |
